Table 1.

Prognostic value of Plk3 expression for the disease-free survival by Cox proportional hazards model

Variables	Disease-free survival
	HR (95% CI)	P-value
Univariate analysis
Age (≥60 vs <60 years)	1.488 (0.968–2.287)	0.070
Gleason score (>7 vs =7 vs < 7)	9.464 (1.319–67.921)	0.025*
Tumor stage (T2–T4 vs T1)	2.972 (1.732–5.102)	<0.001***
Lymph node stage (N1 vs N 0)	1.801 (1.111–2.920)	0.017
Distant metastasis (M1 vs M0)	0.049 (0–2488134.592)	0.740
PSA (≥4 vs <4)	3.410 (1.644–7.075)	0.001**
Plk3 expression (high vs low)	1.855 (1.048–3.285)	0.034*
Multivariate analysis
Gleason score (>7 vs = 7 vs < 7)	5.709 (0.789–41.328)	0.085
Tumor stage (T2–T4 vs T1)	2.763 (1.1607–4.751)	<0.00024***
Plk3 expression (high vs low)	1.933 (1.091–3.639)	0.025*

Note:

^*P<0.05,

^**P<0.01, and

^***P<0.001. Statically significant P-values are shown in bold.

Abbreviations: Plk3, polo-like kinase 3; PSA, prostate-specific antigen.